Red blood cell transfusions have reduced morbidity and mortality for patients with sickle cell disease (SCD). Transfusions can lead to erythrocyte alloimmunization, however, with serious complications for the patient including life-threatening delayed hemolytic transfusion reactions (DHTRs) and difficulty in finding compatible units, which can cause transfusion delays. In this review, we will discuss the risk factors associated with alloimmunization with emphasis on possible mechanisms that can trigger DHTR in SCD, and describe the challenges in transfusion management of these patients, including opportunities and emerging approaches for minimizing this life-threatening complication.
Introduction
Blood transfusion remains a cornerstone of treatment of patients with sickle cell disease (SCD). Despite improved patient outcomes with hydroxyurea administration, indications for chronic transfusions have increased in the last ten years and are associated with considerable reduction in morbidity and mortality, most notably in preventing first stroke in children. [1] [2] [3] However, transfusions can lead to erythrocyte alloimmunization with serious complications for the patient. These antibodies are often directed against antigens expressed on red blood cells (RBC) of Caucasian individuals, which represent the majority of donors in western countries. 4 Finding compatible units lacking those antigens can sometimes be difficult, and identifying and characterizing the antibodies can be time-consuming and laborious, causing transfusion delays. Genetic as well as acquired patient-related factors are likely to influence the process of alloimmunization.
The most serious consequence of alloimmunization in SCD patients is the risk of developing a delayed hemolytic transfusion reaction (DHTR), which can be life-threatening. In many cases of DHTR in SCD, the patient's hemoglobin level falls below the pretransfusion level,
suggesting that in addition to hemolysis of the transfused RBCs, the patient's own RBCs are lysed, a condition known as hyperhemolysis. Additional transfusions may exacerbate the hemolysis and further worsen the degree of anemia. The destruction of the patient's own RBCs in DHTR of SCD is partly explained by presence of autoantibodies 5 since alloimmunization is known to trigger autoantibody production. However, DHTR/hyperhemolysis cases have also been reported in the absence of detectable allo-or autoantibodies.
In this review, we will discuss the known risk factors associated with alloimmunization, then emphasize possible mechanisms that can trigger autoimmunization and DHTR in SCD, and
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finally describe the challenges in transfusion management of these patients. We will emphasize opportunities and emerging approaches for minimizing this life-threatening complication.
RBC alloimmunization pathobiology
Alloimmunization to erythrocytes involves multiple steps including RBC antigen recognition, processing and presentation of antigen by HLA class II to T cell receptor (TCR), activation of CD4 helper T cells, interaction of T and B cells, and finally B cell differentiation into plasma cells ( Fig. 1 ). Murine and human studies have shown that the process of alloimmunization to RBC antigens can be modulated at each step through acquired and genetic factors, although the relevance of these factors in SCD alloimmunization has not been completely elucidated.
Antigenic differences between donor and recipient RBCs are requisite for the initial trigger for alloimmunization. In SCD, multiple studies have shown that alloimmunization risk increases with increasing number of transfusions. [6] [7] [8] [9] [10] [11] In addition, women show a higher rate of alloimmunization, 11 partially explained by exposure through pregnancy. 12 Not all patients develop alloantibodies following exposure to transfused RBCs. This fact pertains not only to patients with SCD but also to all transfused recipients. A recent mathematical modeling study has supported the hypothesis that alloimmunized patients represent a genetically distinct group with an increased susceptibility to RBC sensitization. 13 Within this group only 30% will actually make antibodies, raising the possibility that patientrelated factors including the nature of the underlying disease may influence alloimmunization in patients with inherited risks. In the following sections, we aim to describe the antigenic RBC determinants in SCD alloimmunization and identify host-susceptibility factors including those common to any patient population as well as those specific to SCD alloimmunization.
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Antigenic differences between donor and recipient RBCs: the initial trigger of alloimmunization SCD patients are among one of the most frequently alloimmunized transfused population, most likely due to polymorphic differences in immunogenic RBC antigens between the predominantly Caucasian general blood donors and patients of predominantly African descent. In SCD, the published rate of alloimmunization ranges from 20% to 50%. 4, 8 However, SCD patients in Uganda and Jamaica, where donors and patients are racially more homogenous, have reported alloimmunization rates of only 6.1 % and 2.6%, respectively 14, 15 which are comparable to alloimmunization frequencies reported for the general population of these two countries (1-6%). 16 The overall lower use of blood products and blood transfusion therapy for SCD in these countries, in part because of concerns about the safety and availability of blood, also may contribute to these lower alloimmunization rates. Prospective comparison of alloimmunization rates per unit transfused between SCD patients in Uganda and Jamaica with those in western countries will be needed to determine the importance of RBC racial and ethnic differences between donors and recipients on alloimmunization rates.
In patients with thalassemia, who are also highly transfused but generally share a more similar ethnic background with blood donors, the rate of alloimmunization is about 10%. 17 But when the general donor pool is mostly Caucasian, Asian patients with thalassemia have an increased rate of alloimmunization compared to Caucasian patients. 18 Together, these observations support the idea that racial antigenic differences account for increased alloimmunization rates.
Antigenic differences between donors and SCD patients are represented at 3 levels of increasing complexity (Table 1) . First, the prevalence of some common but highly immunogenic antigens differs substantially between donors and transfusion recipients.
Specifically, C and E in the Rhesus (RH) blood group, K in the Kell (KEL), Fy a in the Duffy in Caucasians than in individuals of African descent. Not surprisingly, antibodies against these commons antigens are most frequently identified in SCD patients. 8 Matching for E, C and K reduced the rate of alloimmunization in chronically transfused SCD patients from 3% to 0.5% per unit 19 and is now the standard of care in many western countries, while prophylactic extended matching for RH, KEL, FY, JK and MNS has been shown to be even more effective. 19, 20 and MNS (absence of U) blood groups (Table 1) , antibodies against which have been shown to cause RBC destruction. 34 Transfusion management for these patients, especially once alloimmunization has occurred, can be extremely challenging. This scenario is best illustrated by the U-negative phenotype of the MNS blood group, which is found in at least 1% of the SCD patients, depending on their country of origin. Low blood donation rates, as well as poor donor eligibility due to higher prevalence of infectious markers in individuals from African countries, contribute to the low supply of U-negative and other rare Black blood types.
Because of the short blood supply in all western countries, U-negative blood is mainly reserved for patients who have already formed anti-U alloantibodies. For patients with rare inserm-00696264, version 1 -11 May 2012
RH blood groups such as Hr S , Hr B or RH46 negative phenotypes, the situation is even more complex since few facilities have the corresponding antigen negative supply.
Individual-specific susceptibility factors
Similar to its role in platelet antigen specific alloimmunization, 35 the HLA II genotype of the patient is a key predictor of an individual's response to RBC antigens, and is likely to influence predisposition to the RBC antibody responder status. 36;37 For example, in
Caucasians antibody formation to the RBC-specific Fy a antigen is strongly associated with the DRB1 04 and DRB1 15 alleles, analogous to observations that HLA-DRB3*0101 and HLA-DQB1*0201 are the key players for platelet antigen HPA-1a alloimmunization. Compared to Fy a , the erythrocyte K antigen is highly immunogenic, probably because the potential K antigen derived peptides can bind to multiple HLA molecules, as indicated by the wide variety of HLA II phenotypes found in individuals producing anti-K. 36 The HLA-DRB1*1503 allele has been associated with an increased risk of RBC alloimmunization, regardless of the antibody specificity, while HLA-DRB1*0901 appears to confer protection against alloimmunization. 38 These latter data suggest that beyond the direct link between HLA II and antibody specificity, HLA alleles may also modulate alloimmunization at a non-antigen specific level. In a small study of chronically transfused patients with SCD, reduced peripheral Treg suppressive function was found in antibody responders compared to non-responders. 41 If confirmed in larger cohorts, this information may help identify T cell associated molecular markers that can accurately predict antibody responders. A higher proportion of Th2 cells, known to regulate humoral immunity, were detected in a subset of alloimmunized SCD patients, documenting a skewed Th2 response in a subgroup of SCD antibody responders ( Fig. 1) . 41 Since SCD was the only alloimmunized transfused patient population in that study, however, it remains undefined if Th2 skewing is a unique feature of alloimmunized SCD patients or also applicable to other immune responders. Although no differences were evident in Th1 and Th17 cell frequencies between alloimmunized and non-alloimmunized SCD patients, the proportion of Th17 cells, which drive tissue inflammation 42 as well as circulating TGF-β and IL-6, known to promote human Th17 differentiation 43 , were higher in transfused SCD cohorts than in healthy race-matched controls, 41 consistent with the proinflammatory nature of SCD (see below).
SCD-specific susceptibility factors
A main feature of SCD is a chronic inflammatory state even in steady state as indicated by increased levels of C-reactive protein, 44, 45 and inflammatory cytokines (IL-1, IL-6 and interferon- 46;47 compared to healthy controls, as well as an increased white blood cell (WBC) count that is recognized as a risk factor for disease severity. 48 In mouse models, certain proinflammatory stimuli enhance alloimmunization, 49 ,39 most likely due to additional transfused RBC consumption by splenic and liver dendritic cells (DCs), which are potent inducers of alloimmunization. 50 The recent observation that a previous 52 Extrapolating these data to humans must be done with caution, however, since there are inherent differences between clinical features of human SCD and available mouse models, 53 and only one example of alloimmunization (to HOD antigen) following a single transfusion was studied. 52 It is currently unknown if alloimmunization rates differ depending on the presence or absence of clinical complications of SCD. For example, it remains unclear whether patients during acute vaso-occlusive crisis (VOC) have an altered alloimmunization potential. VOC, compared to steady state SCD, is associated with increased inflammatory factors, such as neutrophil chemotaxis and monocyte phagocytosis, but also increased production of IL-6 and augmentation of TNF- production. 54, 55 The increased inflammatory state in VOC could, therefore, affect alloimmunization rates. In contrast, transfusion in the absence of inflammation induces antigenic specific tolerance in mouse models. 56 Children with SCD who are chronically transfused might have less inflammation, which could explain their lower rate of alloimmunization. 11, 57 However, circulating levels of IL-6 were still elevated in a cohort of chronically transfused young SCD patients as compared to healthy controls, 58 suggesting that the inflammatory state of SCD may continue despite transfusions.
Longitudinal studies involving measurements of inflammatory markers are needed to test whether chronic transfusions, especially with concomitant iron chelation, can reduce inflammation and lower the risk of developing alloantibodies.
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Another important issue, recently addressed by Verduzo and Nathan, relates to the effects of age at transfusion initiation on alloimmunization rates in SCD. 59 Chronic transfusion protocols for prevention of primary stroke typically begin in childhood, but at an older age than children with thalassemia who begin chronic transfusions in infancy. Multiple studies have shown that the number of cumulative transfusions increases the rate of alloimmunization, 6-11 but it is not known whether chronic transfusions initiated at an early age can lower alloimmunization rates in SCD, perhaps by inducing immune tolerance.
Besides these acquired factors, identification of genetic markers predictive of immunization in SCD is an important area of investigation. A polymorphism in the immunoregulatory TRIM21 gene, in close proximity to the beta-globin locus, was recently shown to be associated with an increased rate of SCD alloimmunization, especially in early childhood. 60 In mice lacking TRIM21, no significant increases in alloimmunization frequency against RBC or platelets were observed, although the mouse model did not have SCD. 61 Genome-wide association studies and whole exome sequencing of large cohorts of patients with SCD receiving transfusions should facilitate the identification of genetic predictors of alloimmunization, but these studies will only be informative if performed in conjunction with an accurate laboratory phenotype, which requires routine and thorough testing for RBC alloantibodies.
Autoantibody formation following alloimmunization
Development of RBC autoantibodies following alloimmunization occurs in transfused populations without hemoglobinopathies, although the rates are much higher in transfused patients with thalassemia 18 and SCD 62-66 with a cumulative incidence of about 6 to 10%. 
Delayed hemolytic transfusion reaction (DHTR)
The most life-threatening consequence of alloimmunization in SCD is the development of DHTR with hyperhemolysis. This type of hemolytic reaction is unpredictable and potentially under-recognized because its clinical presentation may resemble a VOC. 
Main features and hypothesized mechanisms in SCD
Classically in DHTR, alloantibodies have developed against antigens on transfused RBCs.
These antibodies are often not detected in the serum during the pre-transfusion screening test, and therefore presumably result from remote antigenic exposure and waning of alloantibody titers, followed by current immune restimulation. 78 This scenario occurs commonly when detailed and longitudinal transfusion records are not maintained for patients with SCD.
In SCD, cases also exist where the newly formed antibodies were not known to be classically hemolytic, but their pathogenicity was possibly mediated by activated effector cells in SCD such as hyper-reactive macrophages or NK cells with increased FcR expression. 79 In most reported cases (Table S1 ), patients harboring these antibodies were transfused because of an 81 and also potentiate their destruction by macrophages through PS receptors.
Cases of DHTR also exist where no detectable antibodies are found in the post-transfusion screening test (see below and Table S1 ). The mechanism of hyperhemolysis without detectable antibodies is poorly understood, and therefore difficult to explain, prevent, or treat.
In SCD, the process has been attributed to macrophage activation, bystander hemolysis, In 20 out of 73 cases, no additional antibodies were identified in the post-DHTR screening tests. These cases included patients without alloantibodies and documented alloimmunized patients who received matched units for those target antigens. The lack of detectable new antibodies in the post-transfusion screening test is consistent with a non-antibody dependent mechanism of post-transfusion hemolysis as described above.
Diagnosis and management of DHTR
The diagnosis of DHTR in SCD is frequently missed because clinical symptoms resembling Current management of DHTR in SCD remains controversial since the exact mechanisms remain unclear, especially when antibodies cannot be detected, and also because some of the treatments used in DHTR may be deleterious for SCD patients. For example, corticosteroids can reduce antibody-mediated hemolysis, but may lead to a rebound phenomenon with an increase of SCD-related symptoms. 98 IVIg, also commonly used for DHTR, 5, 8, 9, 19 carries a small risk of thromboembolic complications due to hyperviscosity; 99 however, IVIg is effective for DHTR even in cases where no antibody or new antibody is detected,due to the inhibitory effects of IVIg on the cellular immune response, including inflammation and macrophage phagocytic function associated with SCD ( Fig. 1) . Erythropoiesis stimulating agents can also be given to reticulocytopenic patients. 100 Rituximab may be another potential treatment option, especially when hemolysis occurs in a known immunized patient. In one reported case, rituximab was used prophylactically in a SCD patient with prior DHTR episodes, to prevent recurrence of autoantibodies and appearance of new alloantibodies. 5 Rituximab given with steroids and darbopoietin alpha was also effective in treating SCD antibody-mediated hemolysis. 101 However, the risk to benefit ratio has not been defined in this setting, and prospective studies are warranted. In most cases of DHTR, further transfusions should be withheld to avoid exacerbating the ongoing hemolytic reaction. Since withholding transfusions for patients with cerebral vasculopathy could increase the likelihood of stroke, the risks and benefits of additional transfusions should be carefully evaluated for each patient with DHTR.
Transfusion management strategies to prevent alloimmunization and DHTR

Recommendations for clinical care
Transfusion of leukoreduced RBC units, which are phenotypically matched for immunogenic RH/KEL blood groups and then cross-matched with a recent serum sample, should be the minimum standard of care for patients with SCD (Fig. 2) . Despite the associated costs and effort, an additional extended phenotype to other blood groups performed at diagnosis can save valuable time in the transfusion management of patients with multiple allo-and autoantibodies during acute situations. The utility and cost-effectiveness of an early extended phenotype matching has not been reported. With technological advances in genomics, high throughput DNA typing platforms will become cheaper for donor typing, and should reduce the need for rare serological reagents to find rare compatible donors. 102 This approach will still depend on increasing the pool of donors with African origin, and strategies to promote blood donation in these communities should be an ongoing priority (see below).
For every transfusion, all known antibodies in the patient's history must be considered to minimize the risk of antibody-mediated DHTR that follows immune restimulation. It is critical to have well-maintained patient records, and if possible, to monitor patients with antibody screening following every transfusion, testing for development of antibodies that may become undetectable before the next transfusion. Based on the study by Schonewille et al., 12 post-transfusion screening tests should ideally be performed twice, shortly after transfusion (about 3-7 days) and also a longer period of time after transfusion (4-8 weeks) for optimal detection of antibodies. Figure 2 illustrates an algorithm describing the interplay between antibody screening tests and the patient's own RBC phenotype. Ongoing studies should explore novel approaches to inhibit alloimmunization in SCD.
Immunomodulatory therapies such as the use of immune-cell-depleting agents, costimulatory blockade, and cytokine blockade may be effective in suppressing alloimmunization (Fig. 1 ), although their use should be carefully balanced against the risk of infections for SCD patients.
Rituximab, a mouse-human chimeric antihuman monoclonal antibody that binds CD20
expressed on all B cell, has been used successfully to treat autoantibody production and hemolysis in SCD, 101, 106 presumably by depleting pathogenic antibody-producing B cells. With regard to current transfusion management of SCD patients, we recommend performing an extended phenotype for all patients with SCD at diagnosis, careful monitoring of laboratory tests before and following every transfusion, and a well-maintained electronic system of patient transfusion history. Molecular tools to type most blood group variants have been developed, 112 and ongoing studies to determine the incidence and clinical significance of antibodies against variants are needed to develop cost-effective genotyping tests for those antigens whose associated antibodies are clinically significant. In parallel, strategies to promote blood donation amongst individuals of African origin should remain a high priority for increasing the donor pool of antigen-matched blood for SCD patients.
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